載入中
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
前收盤價
US$2.85
−US$0.04 · -1.38%
盤前
US$2.82
−US$0.03 · -1.05%
10月12日 上午8:15 ET
盤中時間採用ET。市場資料可能有所延遲。
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
日內區間
目前US$2.85
52週區間
目前US$2.85
盤中時間採用ET。市場資料可能有所延遲。
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
日內區間
目前US$2.85
52週區間
目前US$2.85
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 122.5萬 USD | — | — | — | — |
| 銷貨成本 | 50.5萬 USD | 5000 USD | 5000 USD | 4000 USD | 2000 USD |
| 毛利 | 72萬 USD | −5000 USD | −5000 USD | −4000 USD | −2000 USD |
| 研究與開發 | 377.7萬 USD | 619.9萬 USD | 1337.1萬 USD | 1702.7萬 USD | 2025.7萬 USD |
| 銷售、一般及管理費用 | 1306.1萬 USD | 1350萬 USD | 1421.1萬 USD | 2730.4萬 USD | 7494.2萬 USD |
| 營業費用 | 1694.4萬 USD | 1969.9萬 USD | 2758.2萬 USD | 4433.1萬 USD | 9519.9萬 USD |
| 利息收入 | 1.2萬 USD | 4.4萬 USD | 49.4萬 USD | 24.9萬 USD | 18 USD |
| 利息支出 | 67.1萬 USD | 107.9萬 USD | 12萬 USD | — | 1.8萬 USD |
| 折舊和攤銷 | 14.3萬 USD | 5000 USD | 5000 USD | 4000 USD | 2000 USD |
| 營業利益 | −1622.4萬 USD | −1970.4萬 USD | −2758.7萬 USD | −4433.5萬 USD | −9520.1萬 USD |
| 淨利 | −2862.2萬 USD | −2512.6萬 USD | −3015萬 USD | −3975.4萬 USD | −9306.3萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.00
下跌空間 29.82%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年4月2日 | 1:10 | — | — |
已生效 2024年4月2日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI
AdvisorShares Psychedelics ETFPSIL
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
